Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- 25 September 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 13 (11), 927-935
- https://doi.org/10.1016/s1473-3099(13)70257-3
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Dolutegravir in antiretroviral-naive adults with HIV-1AIDS, 2013
- No Association of Abacavir Use With Myocardial InfarctionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialThe Lancet Infectious Diseases, 2011
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase InhibitorAntimicrobial Agents and Chemotherapy, 2011
- Integrase inhibitors in the treatment of HIV-1 infectionJournal of Antimicrobial Chemotherapy, 2010
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialThe Journal of Infectious Diseases, 2010
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Designing and interpreting HIV noninferiority trials in naive and experienced patientsAIDS, 2008
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- The Effect of Trimethoprim on Serum CreatinineBJU International, 1985